Evidence map›Paper›PMID 42764959›Full record

ReviewActa pharmaceutica Sinica. B2026

Deconvoluting the multi-faceted roles of alternative splicing events in cancer: From underlying mechanisms to innovative therapeutics.

Lei Hu, Xiaofang Wang, Bo Fan, Qian Zhao, Yajun Zhong, Yingying Lu, Minru Liao, Hongyao Li, Xiangyu Fu, Huiping Wang and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lei HuDepartment of Urology, Institute of Precision Drug Innovation and Cancer Center, The Second Hospital of Dalian Medical University, Dalian 116023, China.
Xiaofang WangState Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Bo FanDepartment of Urology, Institute of Precision Drug Innovation and Cancer Center, The Second Hospital of Dalian Medical University, Dalian 116023, China.
Qian ZhaoState Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Yajun ZhongState Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Yingying LuDepartment of Urology, Institute of Precision Drug Innovation and Cancer Center, The Second Hospital of Dalian Medical University, Dalian 116023, China.
Minru LiaoDepartment of Urology, Institute of Precision Drug Innovation and Cancer Center, The Second Hospital of Dalian Medical University, Dalian 116023, China.
Hongyao LiDepartment of Urology, Institute of Precision Drug Innovation and Cancer Center, The Second Hospital of Dalian Medical University, Dalian 116023, China.
Xiangyu FuSichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Huiping WangSichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Cheng DuDepartment of Oncology, General Hospital of Northern Theater Command, Shenyang 110316, China.
Bo HanState Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Leilei FuDepartment of Urology, Institute of Precision Drug Innovation and Cancer Center, The Second Hospital of Dalian Medical University, Dalian 116023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative splicing (AS) is well-known to be a critical mechanism to enhance proteomic diversity from a limited genome. Dysregulation of AS may represent a key tumor-specific molecular feature; thereby driving tumorigenesis and progression. Elucidating the mechanisms underlying AS dysregulation in oncogenesis is paramount for developing more novel therapeutic targets and agents. Thus, in this review, we comprehensively demonstrate the pivotal roles of AS dysregulation across the 14 established cancer hallmarks. We systematically summarize current therapeutic targets and related strategies for targeting AS in cancer, including small molecules and antisense oligonucleotides (ASOs). Moreover, we further discuss the progress, challenges, and potential solutions in drug development by providing both preclinical data and clinical trial outcomes for AS-targeted therapies. In summary, this review aims to deconvolute the multi-faceted roles of alternative splicing events in cancer from underlying mechanisms to innovative therapeutics.

Indexed as

Alternative splicingAntisense oligonucleotideCancer therapyClinical translationMolecular targetSmall molecule compoundTumor hallmarkUnderlying mechanism

Identifiers

PMID42764959
PMCPMC13589949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.